- Home
- STXS vs BWAY Comparison
STXS vs BWAY Comparison
Compare STXS & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- BWAY
- Stock Information
- Founded
- STXS 1990
- BWAY 2003
- Country
- STXS United States
- BWAY Israel
- Employees
- STXS N/A
- BWAY N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BWAY Medical/Dental Instruments
- Sector
- STXS Health Care
- BWAY Health Care
- Exchange
- STXS Nasdaq
- BWAY Nasdaq
- Market Cap
- STXS N/A
- BWAY 177.4M
- IPO Year
- STXS 2004
- BWAY 2019
- Fundamental
- Price
- STXS $2.19
- BWAY $10.69
- Analyst Decision
- STXS Strong Buy
- BWAY Strong Buy
- Analyst Count
- STXS 2
- BWAY 3
- Target Price
- STXS $4.50
- BWAY $13.17
- AVG Volume (30 Days)
- STXS 337.8K
- BWAY 50.5K
- Earning Date
- STXS 03-03-2025
- BWAY 03-05-2025
- Dividend Yield
- STXS N/A
- BWAY N/A
- EPS Growth
- STXS N/A
- BWAY N/A
- EPS
- STXS N/A
- BWAY 0.04
- Revenue
- STXS $25,143,000.00
- BWAY $38,631,000.00
- Revenue This Year
- STXS $3.73
- BWAY $388.82
- Revenue Next Year
- STXS $54.27
- BWAY $18.70
- P/E Ratio
- STXS N/A
- BWAY $137.57
- Revenue Growth
- STXS N/A
- BWAY 34.19
- 52 Week Low
- STXS $1.66
- BWAY $4.61
- 52 Week High
- STXS $3.29
- BWAY $11.25
- Technical
- Relative Strength Index (RSI)
- STXS 48.66
- BWAY 62.56
- Support Level
- STXS $2.21
- BWAY $10.08
- Resistance Level
- STXS $2.22
- BWAY $11.25
- Average True Range (ATR)
- STXS 0.13
- BWAY 0.37
- MACD
- STXS -0.01
- BWAY 0.15
- Stochastic Oscillator
- STXS 23.19
- BWAY 72.96
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.